Last updated: November 9, 2026
Disulfiram is a mature, low-cost alcohol-use-disorder medicine with no meaningful U.S. patent exclusivity, limited commercial investment, and declining branded relevance. The U.S. market is supplied primarily through generic tablets, while demand is constrained by adherence problems, adverse-effect concerns, and competition from naltrexone and acamprosate. No public company reports disulfiram revenue as a material standalone product line.
What is the current market position of disulfiram?
Disulfiram is an aldehyde dehydrogenase inhibitor used as a deterrent therapy for alcohol dependence. It causes an unpleasant reaction after alcohol exposure and is intended for patients who understand the treatment risks and can maintain adherence.
The product has a narrow commercial profile:
| Market factor |
Current position |
| Active ingredient |
Disulfiram |
| Primary indication |
Alcohol dependence or alcohol-use disorder |
| U.S. dosage form |
Oral tablets, commonly 250 mg and 500 mg |
| Branded U.S. product |
Antabuse, historically marketed by Odyssey Pharmaceuticals; no meaningful current branded presence |
| U.S. supply |
Generic manufacturers and distributors |
| Patent status |
Foundational composition and product patents expired decades ago |
| Regulatory exclusivity |
None of commercial significance |
| Orange Book position |
No active branded exclusivity protecting disulfiram tablets |
| Biosimilar exposure |
Not applicable; disulfiram is a small molecule |
| Commercial pricing |
Low-cost generic pricing, often subject to pharmacy and wholesaler variation |
| Primary competitors |
Naltrexone, extended-release injectable naltrexone, acamprosate, behavioral treatment, and off-label pharmacotherapies |
Disulfiram remains clinically available, but it is no longer a high-growth pharmaceutical asset. Its market is driven by prescription volume, generic availability, and treatment-practice patterns rather than intellectual property.
How large is the disulfiram market?
Public sources do not provide a reliable, disulfiram-specific global revenue figure. Disulfiram is generally grouped into broader alcohol-use-disorder, addiction-treatment, or generic pharmaceutical market categories. Manufacturer filings typically do not report the medicine as a separate revenue line.
The financial profile is therefore better assessed through market structure:
- The medicine is genericized in the United States and major developed markets.
- Tablet manufacturing is technically straightforward.
- Multiple suppliers can compete on price.
- Low per-prescription value limits promotional investment.
- Revenue is fragmented across manufacturers, wholesalers, pharmacies, and institutional purchasers.
- Clinical use is smaller than the diagnosed alcohol-use-disorder population because disulfiram requires high adherence and patient acceptance.
The addressable clinical population is substantial. The National Institute on Alcohol Abuse and Alcoholism estimated that 28.5 million U.S. adults had alcohol use disorder in 2021, but only a minority received treatment (National Institute on Alcohol Abuse and Alcoholism, 2023). That gap does not translate directly into disulfiram opportunity because treatment guidelines and prescribing behavior favor other medicines for many patients.
What is the financial trajectory for disulfiram?
Disulfiram’s financial trajectory is mature to declining in branded terms and stable to low-growth in generic terms.
Revenue drivers
The main revenue drivers are:
- Prescription volume in alcohol-use-disorder treatment
- Generic tablet availability
- Public-sector and institutional procurement
- International access to low-cost oral treatment
- Use in supervised or highly structured treatment programs
Revenue constraints
The principal constraints are:
- Poor adherence when treatment is unsupervised
- Risk of severe reactions with alcohol exposure
- Limited use in patients with liver disease or other contraindications
- Competition from naltrexone and acamprosate
- Limited physician preference for a deterrent-based mechanism
- Low pricing and weak manufacturer differentiation
- Absence of effective product exclusivity
Disulfiram is unlikely to produce substantial standalone revenue for a large pharmaceutical company without a differentiated delivery system, adherence technology, combination product, or new regulatory indication.
Commercial outlook by business model
| Business model |
Outlook |
| Branded oral disulfiram |
Weak |
| U.S. generic tablets |
Stable, low-margin |
| Government and institutional supply |
Potentially durable but price-sensitive |
| New long-acting formulation |
Potentially differentiated, but requires clinical and regulatory investment |
| Disulfiram repurposing for oncology or infectious disease |
High scientific uncertainty and no established commercial pathway |
| Digital adherence or supervised-dosing program |
Niche opportunity tied to care delivery rather than drug margin |
When does disulfiram lose exclusivity?
Disulfiram lost meaningful U.S. exclusivity many decades ago. The active ingredient was introduced in the mid-20th century, and modern generic competition is long established.
No active composition-of-matter or primary product patent currently prevents generic disulfiram tablet competition in the United States. Any historical patents covering the original molecule or early product use expired long before the current market.
The commercial result is clear:
- No patent-based launch delay exists for standard disulfiram tablets.
- No pediatric exclusivity materially affects the product.
- No orphan-drug exclusivity protects the alcohol-dependence indication.
- No new chemical entity exclusivity applies.
- No current patent term extension is commercially relevant.
What is the FDA regulatory status of disulfiram?
Disulfiram remains an FDA-recognized prescription medicine for the management of selected patients with chronic alcoholism who are informed of the risks and are motivated to abstain from alcohol.
The historical branded product, Antabuse, has been discontinued or is no longer the principal commercial source in the U.S. market. FDA drug-discontinuation records distinguish product discontinuation from safety withdrawal; a discontinued brand does not mean that the active ingredient is prohibited or unavailable through approved generic products.
Current labeling emphasizes that:
- Patients must not consume alcohol during treatment.
- Alcohol can be present in foods, medicines, sauces, cosmetics, and other products.
- The reaction can occur during treatment and for a period after discontinuation.
- Treatment should be used selectively and with patient education.
- Hepatic toxicity is a material safety consideration.
FDA labeling and DailyMed records remain the most relevant sources for product-specific dosage, contraindication, warning, and manufacturer information (U.S. National Library of Medicine, 2024; FDA, 2024).
What is the Orange Book status of disulfiram?
Disulfiram tablets do not have a meaningful Orange Book exclusivity position.
The Orange Book is relevant because it identifies approved drug products, reference-listed drugs, patent certifications, and certain regulatory exclusivities. For a mature generic product such as disulfiram:
- The original branded reference product no longer creates a practical exclusivity barrier.
- Generic applicants can rely on abbreviated new drug application pathways.
- Standard Paragraph IV litigation risk is limited because there are no material active patents protecting ordinary disulfiram tablets.
- Any listed patent related to a specific product, formulation, or method must be evaluated separately from the active ingredient.
A generic applicant seeking approval for standard disulfiram tablets therefore faces ordinary ANDA requirements rather than a significant patent-certification obstacle.
Which companies are challenging disulfiram patents?
No major current Paragraph IV campaign is associated with standard disulfiram tablets. The market is already genericized, and generic suppliers generally compete without needing to defeat a valuable active patent estate.
Companies involved in disulfiram supply may change over time because ANDA ownership, manufacturing, and distribution arrangements are frequently transferred. The relevant competitive set includes generic manufacturers, contract manufacturers, and pharmaceutical distributors rather than branded innovators.
No material active U.S. litigation campaign is widely associated with the standard oral product. Patent disputes would be more likely if a company introduced a new delivery system, fixed-dose combination, controlled-release formulation, or new therapeutic use.
What formulations are protected by disulfiram patents?
Standard immediate-release disulfiram tablets have little or no meaningful remaining patent protection. Potentially protectable developments would involve product differentiation rather than the old active ingredient.
Potential formulation strategies
| Strategy |
Commercial rationale |
Patent risk |
| Extended-release tablet |
Reduce dosing frequency and support adherence |
Formulation and release-profile patents could apply |
| Long-acting injectable |
Improve supervision and persistence |
High development, device, manufacturing, and clinical risk |
| Implant or depot system |
Provide prolonged exposure |
Potentially strong product and process IP if clinically successful |
| Abuse-deterrent or alcohol-triggered delivery |
Target compliance and safety |
Requires proof of clinical utility |
| Fixed-dose combination |
Combine disulfiram with another addiction-treatment agent |
Combination and method-of-use claims possible |
| Digital adherence package |
Link dosing to monitoring or supervised care |
Software and service protection may be more relevant than drug patents |
A new formulation could receive patent protection for composition, particle size, release profile, device architecture, manufacturing process, or treatment method. Those rights would protect the new product, not the underlying disulfiram molecule.
How strong is the disulfiram patent estate?
The patent estate for conventional disulfiram is weak from an exclusivity perspective.
| Patent-estate category |
Assessment |
| Composition of matter |
Expired |
| Standard tablet formulation |
Broad generic competition |
| Core alcohol-dependence indication |
Long-established and not commercially exclusive |
| Method-of-use claims |
Potentially narrow and vulnerable if based on known use |
| Manufacturing process |
Limited strategic value unless it creates a cost or quality advantage |
| New delivery technology |
Potentially valuable if clinically differentiated |
| International coverage |
Generally mature and fragmented |
| Freedom-to-operate for generic tablets |
Broad, subject to jurisdiction-specific review |
A new patent portfolio could still be valuable if it supports a formulation with better adherence, a controlled-release profile, or a clinically meaningful safety advantage. Claims based only on conventional dosing or routine use would face greater validity and obviousness pressure.
What generic entry risks exist for disulfiram?
Generic entry risk is already realized rather than prospective. Standard tablets are exposed to:
- Price competition from multiple suppliers
- Supply interruptions if manufacturers exit a low-margin market
- Wholesaler concentration
- Contract-manufacturing changes
- Substitution under pharmacy benefit plans
- Procurement pressure from public and institutional purchasers
The principal commercial risk is not a future generic launch. It is erosion of supplier economics and periodic availability problems in a market with limited redundancy.
For a new branded disulfiram formulation, the risk profile would change. An innovator would need to defend patents against:
- ANDA filings directed to the formulation
- Paragraph IV invalidity or non-infringement claims
- Generic substitution after patent expiry
- Off-label use of low-cost immediate-release tablets
- Physician reluctance to switch stable patients
What patent litigation affects disulfiram?
There is no material, widely reported patent litigation campaign affecting ordinary U.S. disulfiram tablets. The absence of litigation reflects the age of the product and the lack of commercially important active patents.
Future litigation would most likely arise from a differentiated product. Relevant claims could cover:
- Controlled-release matrices
- Injectable suspensions
- Implant systems
- Specific dosing schedules
- Combination treatment
- Patient-selection criteria
- Manufacturing methods
- Delivery devices
Method-of-use patents would require careful enforcement analysis because alcohol-use-disorder treatment involves established clinical practices, generic substitution, and potential off-label use.
Are there licensing deals for disulfiram?
No major current licensing transaction has made conventional disulfiram a significant pharmaceutical licensing asset. The active ingredient is inexpensive and widely available, which reduces the value of simple supply or formulation licenses.
Licensing value could emerge in three areas:
- A validated long-acting delivery platform.
- A clinically supported new indication with patent protection.
- A combination of disulfiram with adherence monitoring or supervised treatment infrastructure.
Repurposing efforts involving disulfiram in cancer, infection, or neurodegenerative disease have generated scientific interest, but scientific publications or early-stage research do not establish a commercial product, regulatory approval, or durable licensing market.
How does disulfiram compare with naltrexone and acamprosate?
| Attribute |
Disulfiram |
Naltrexone |
Acamprosate |
| Core mechanism |
Alcohol-aversive aldehyde dehydrogenase inhibition |
Opioid receptor antagonism |
Modulates glutamatergic and GABAergic signaling |
| Oral dosing |
Usually daily |
Daily or monthly injectable option |
| Adherence dependence |
High |
Moderate for oral; lower dosing frequency for injectable |
| Generic competition |
Extensive |
Extensive for oral form |
| Differentiated branded product |
Limited |
Extended-release injectable product |
| Key safety issue |
Alcohol-disulfiram reaction and liver toxicity |
Liver concerns, opioid blockade |
| Commercial attractiveness |
Low |
Higher because of injectable option |
| Evidence and prescribing role |
Selective, often supervised use |
Broadly used pharmacotherapy option |
| Patent opportunity |
New delivery systems only |
Long-acting and device-related protection |
Naltrexone has a stronger commercial position because extended-release injectable treatment creates a branded, differentiated product category. Acamprosate competes as an oral generic option without the alcohol-aversive risk associated with disulfiram.
What is the geographic coverage of disulfiram?
Disulfiram has broad historical geographic coverage but uneven current commercial availability. It is used or marketed in multiple regions as a prescription treatment for alcohol dependence, subject to national approval, labeling, and reimbursement.
Geographic commercial conditions vary:
- The United States has a mature generic market.
- European markets generally have established generic or legacy supply.
- Emerging markets may value low acquisition cost but have variable diagnosis and treatment infrastructure.
- Public-sector programs may use disulfiram where supervised administration is feasible.
- Availability can depend on local registration, distributor economics, and manufacturer continuity.
International patent barriers are generally limited for the old active ingredient. Local regulatory registration, manufacturing compliance, and distribution capacity are more important than patent ownership.
What manufacturing and intellectual-property barriers exist?
Manufacturing disulfiram tablets is less complex than manufacturing biologics, sterile injectables, or advanced drug-device products. The main barriers are operational:
- Active pharmaceutical ingredient qualification
- Good manufacturing practice compliance
- Dissolution and content-uniformity performance
- Stable tablet production
- Supplier reliability
- Regulatory maintenance
- Pharmacovigilance and labeling control
For a new long-acting or injectable product, barriers would increase sharply. The sponsor would need validated drug substance and drug product processes, container-closure compatibility, stability data, clinical evidence, device or administration controls, and potentially a stronger patent estate.
What is the generic launch scenario for disulfiram?
A conventional generic launch would face little patent friction but limited revenue upside. The likely commercial sequence is:
- ANDA approval or maintenance of an existing approved product.
- Wholesale and pharmacy contracting.
- Price competition with incumbent generic suppliers.
- Low-cost substitution under payer and pharmacy policies.
- Revenue stabilization at a modest level unless competitors exit.
- Potential margin improvement during a temporary supply disruption.
A branded reformulation would require a different strategy. It would need clinical differentiation, a reimbursement argument, and patents that extend beyond the expired active ingredient.
Key Takeaways
- Disulfiram is a mature generic medicine with no meaningful current U.S. patent exclusivity.
- The standard oral tablet market is low-margin and price-sensitive.
- No major current Paragraph IV campaign or patent litigation materially affects conventional disulfiram.
- The Orange Book does not provide a commercially meaningful exclusivity position for ordinary disulfiram tablets.
- Revenue is fragmented and not separately disclosed by major public companies.
- Naltrexone, particularly extended-release injectable naltrexone, has a stronger commercial position.
- The main opportunity is a differentiated delivery system, not another conventional tablet.
- Manufacturing and regulatory continuity matter more than patent barriers in the existing market.
- Generic entry risk is already embedded in the product’s economics.
- Any investor or licensee case depends on adherence improvement, new delivery technology, or a validated new indication.
FAQs About Disulfiram Market and Patent Strategy
Is Antabuse still sold in the United States?
Antabuse is no longer the dominant U.S. commercial source. FDA-approved generic disulfiram tablets are the relevant supply channel, subject to manufacturer and pharmacy availability.
Does disulfiram have orphan-drug exclusivity?
No commercially relevant orphan-drug exclusivity protects conventional disulfiram for alcohol dependence.
Can a company patent a new disulfiram indication?
A new indication may be patentable if the claimed use is novel, non-obvious, adequately supported, and legally distinguishable from known disulfiram uses. Patentability does not guarantee regulatory approval or market adoption.
Is a long-acting disulfiram injection commercially viable?
It could be commercially differentiated, but viability would depend on clinical adherence benefits, safety, manufacturing feasibility, regulatory approval, reimbursement, and enforceable product claims.
Is disulfiram a biosimilar or biologic product?
No. Disulfiram is a chemically synthesized small molecule. Generic approval follows an ANDA or applicable national generic pathway, not the U.S. biosimilar pathway.
References
-
Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Institute on Alcohol Abuse and Alcoholism. (2023). Alcohol use disorder (AUD) in the United States: Age groups and demographic characteristics. National Institutes of Health. https://www.niaaa.nih.gov/
-
U.S. National Library of Medicine. (2024). DailyMed: Disulfiram tablet labeling. National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/
-
Substance Abuse and Mental Health Services Administration. (2023). Medications for the treatment of alcohol use disorder. U.S. Department of Health and Human Services. https://www.samhsa.gov/medications-substance-use-disorders/medications-alcohol-use-disorder/acamprosate-naltrexone-disulfiram
